Are prescription drugs like new cars? Is pharma’s grand bargain a sham? And who keeps your DNA safe?

We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Nicholas Florko joins us for a discussion of the Trump administration’s efforts to get drug prices into TV ads — and the industry’s vehement opposition. And then we talk about why the best-selling drug in the universe is facing competition overseas but retains a monopoly here in the U.S. Kate Black, 23andMe’s chief privacy officer, talks to us about genetic data security in the age of Facebook leaks and cold-case surprises. Finally, we run through a big-money cancer deal, what to expect from Europe’s big oncology meeting, and the legacy of the late Microsoft co-founder Paul Allen.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy